MCID: ALP061
MIFTS: 38

Alopecia, Androgenetic, 1 malady

Categories: Rare diseases

Aliases & Classifications for Alopecia, Androgenetic, 1

Aliases & Descriptions for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 54 29 13 38
Androgenetic Alopecia 38 50 25 69
Androgenic Alopecia 50 25
Female Pattern Baldness 25
Female Pattern Alopecia 69
Male Pattern Alopecia 25
Male Pattern Baldness 25
Alopecia Androgenetic 52
Pattern Baldness 25

Characteristics:

HPO:

32
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:



External Ids:

OMIM 54 109200

Summaries for Alopecia, Androgenetic, 1

OMIM : 54 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton,... (109200) more...

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to alopecia, androgenetic, 3 and alopecia, androgenetic, 2, and has symptoms including alopecia An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Metabolism of steroid hormones. The drugs Minoxidil and Finasteride have been mentioned in the context of this disorder. Related phenotype is endocrine/exocrine gland.

Genetics Home Reference : 25 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness.

NIH Rare Diseases : 50 androgenetic alopecia is a common form of hair loss in both men and women. in men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness. over time, the hairline recedes to form a characteristic 'm' shape. hair also thins near the top of the head, often progressing to partial or complete baldness. the pattern of hair loss in women differs from men (female pattern hair loss). in women, the hair becomes thinner all over the head, and the hairline does not recede. androgenetic alopecia in women rarely leads to total baldness. a variety of genetic and environmental factors likely play a role in causing this condition. mutations in the ar gene have also been associated with androgenetic alopecia. last updated: 8/19/2011

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 3 Alopecia, Androgenetic, 2

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 3 12.0
2 alopecia, androgenetic, 2 12.0
3 androgenic alopecia 11.1
4 alopecia 11.1
5 hypotrichosis simplex 11.0
6 hypotrichosis 1 11.0
7 alopecia areata 10.4
8 prostatitis 10.3
9 prostate cancer 10.2
10 telogen effluvium 10.2
11 ulceroglandular tularemia 10.2 AR SHBG
12 polyneuropathy 10.2 CYP19A1 SHBG
13 acne 10.1
14 osteogenesis imperfecta 10.1 AR CYP19A1
15 absence of fingerprints congenital milia 10.1 SRD5A1 SRD5A2
16 intraventricular meningioma 10.1 AR SHBG SRD5A2
17 congenital articular rigidity 10.1 AR CYP19A1 SHBG
18 capillary disease 10.1 AR CYP19A1 SHBG
19 third ventricle chordoid glioma 10.1 AR CYP19A1 SRD5A2
20 lichen planopilaris 10.1
21 cervical spinal canal and spinal cord meningioma 10.1 CYP19A1 CYP21A2
22 gaucher's disease 10.1 AR CYP19A1 SHBG
23 diabetes mellitus, insulin-resistant, with acanthosis nigricans 10.1 AR SHBG STS
24 avoidant personality disorder 10.1 AR CYP19A1 SHBG
25 acute thyroiditis 10.1 CYP19A1 SHBG
26 periodic fever, aphthous stomatitis, pharyngitis and adenitis 10.1 AR SRD5A1 SRD5A2
27 exocervical carcinoma 10.0 AR SHBG SRD5A1
28 bent bone dysplasia syndrome 10.0 CYP19A1 CYP21A2
29 liver sarcoma 10.0 CYP19A1 CYP21A2
30 artery disease 10.0
31 heart disease 10.0
32 coronary artery disease 10.0
33 pelvic muscle wasting 10.0 CYP19A1 CYP21A2 SHBG
34 benign essential hypertension 10.0 AR SRD5A1 SRD5A2
35 hypospadias 1, x-linked 10.0 AR CYP19A1 SHBG SRD5A2
36 frontal fibrosing alopecia 9.9
37 hyperandrogenism 9.9
38 dermatitis 9.9
39 psoriasis 9.9
40 sphingolipidosis 9.9 AR CYP19A1 CYP21A2 SHBG
41 borderline personality disorder 9.9 AR CYP19A1 CYP21A2 SRD5A2
42 dystonia-parkinsonism, x-linked 9.9 AR CYP19A1 SHBG SRD5A1
43 epidemic typhus 9.9 CYP19A1 CYP21A2
44 skin hemangioma 9.9 AR CYP19A1 SRD5A1 SRD5A2
45 anaplastic large cell lymphoma 9.9 AR EDA2R SHBG
46 primary biliary cirrhosis 9.8 CYP19A1 CYP21A2 SHBG SRD5A1
47 glioblastoma mesenchymal subtype 9.8 AR CYP19A1 EDA2R SHBG
48 central centrifugal cicatricial alopecia 9.8
49 alexithymia 9.8
50 erosive pustular dermatosis of the scalp 9.8

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Symptoms by clinical synopsis from OMIM:

109200

Clinical features from OMIM:

109200

Human phenotypes related to Alopecia, Androgenetic, 1:

32
id Description HPO Frequency HPO Source Accession
1 alopecia 32 HP:0001596

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.17 XIAP AR CFLAR CYP19A1 SRD5A1 SRD5A2

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minoxidil Approved Phase 3,Phase 1,Phase 2 38304-91-5 4201
2
Finasteride Approved Phase 3,Phase 1,Phase 2 98319-26-7 57363
3
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 152945 6918296
4 Antihypertensive Agents Phase 3,Phase 1,Phase 2
5 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
6 Vasodilator Agents Phase 3,Phase 1,Phase 2
7 5-alpha Reductase Inhibitors Phase 3,Phase 1,Phase 2
8 Hormone Antagonists Phase 3,Phase 1,Phase 2
9 Hormones Phase 3,Phase 1,Phase 2
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
11 Steroid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
12
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
13
Bimatoprost Approved, Investigational Phase 2,Phase 1 155206-00-1 5311027
14
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
15
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
16 HIV Protease Inhibitors Phase 2
17
protease inhibitors Phase 2
18 Proteasome Inhibitors Phase 2
19 Anti-Asthmatic Agents Phase 1, Phase 2
20 Antioxidants Phase 1, Phase 2
21 Autonomic Agents Phase 1, Phase 2
22 Bronchodilator Agents Phase 1, Phase 2
23 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
24 Neurotransmitter Agents Phase 1, Phase 2
25 Peripheral Nervous System Agents Phase 1, Phase 2
26 Protective Agents Phase 1, Phase 2
27 Respiratory System Agents Phase 1, Phase 2
28 Mitogens Phase 1, Phase 2
29
Ethanol Approved Phase 1 64-17-5 702
30
Methyltestosterone Approved Phase 1 58-18-4 6010
31
Testosterone Approved, Investigational Phase 1 58-22-0 6013
32 Anesthetics Phase 1
33 Anabolic Agents Phase 1
34 Androgens Phase 1
35 Antineoplastic Agents, Hormonal Phase 1
36 Estrogens Phase 1
37 Estrogens, Conjugated (USP) Phase 1
38 Micronutrients Phase 1
39 Testosterone 17 beta-cypionate Phase 1
40
Testosterone enanthate Phase 1 315-37-7 9416
41 Testosterone undecanoate Phase 1
42 Trace Elements Phase 1
43 Vitamins Phase 1
44
Cyproterone Acetate Approved, Investigational 427-51-0
45
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757 53477783
46
Ethinyl Estradiol Approved 57-63-6 5991
47 Calcium, Dietary
48 Androgen Antagonists
49 Contraceptive Agents
50 Contraceptive Agents, Male

Interventional clinical trials:

(show all 44)
id Name Status NCT ID Phase
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
2 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3
3 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3
4 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3
5 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3
6 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3
7 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3
8 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3
9 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Recruiting NCT03004469 Phase 3
10 Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Unknown status NCT00471510 Phase 2
11 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Unknown status NCT01501617 Phase 1, Phase 2
12 A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Unknown status NCT01643629 Phase 1, Phase 2
13 Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
14 Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Unknown status NCT01650272 Phase 1, Phase 2
15 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
16 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2
17 Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Completed NCT02280603 Phase 1, Phase 2
18 Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia Completed NCT01286649 Phase 1, Phase 2
19 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
20 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) Completed NCT01451073 Phase 2
21 Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Completed NCT01319370 Phase 2
22 A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss Completed NCT01900041 Phase 2
23 A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2
24 A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2
25 Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Completed NCT00418730 Phase 2
26 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2
27 Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Recruiting NCT02781311 Phase 2
28 AGA Biocellular Stem/Stromal Hair Regenerative Study Recruiting NCT02849470 Phase 1, Phase 2
29 The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia Recruiting NCT03048461 Phase 2
30 Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation Unknown status NCT01655602 Phase 1
31 Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia Unknown status NCT02154503 Phase 1
32 Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Completed NCT02848300 Phase 1
33 Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia Completed NCT01052870 Phase 1
34 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Completed NCT01189279 Phase 1
35 Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers Completed NCT01929330 Phase 1
36 Photosensitization Study in Androgenetic Alopecia Completed NCT02791243 Phase 1
37 Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Not yet recruiting NCT02824380 Phase 1
38 Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA) Terminated NCT02676310 Phase 1
39 Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia Unknown status NCT02393040
40 Effect of PRP on the Therapy for Hair Growth Completed NCT02087319
41 Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases Completed NCT02349399
42 PAI-1 Expression in Non-scarring Hair Loss Recruiting NCT02548689
43 Point-of-Care Adipose-derived Cells for Hair Growth Recruiting NCT02729415 Early Phase 1
44 Minoxidil Response Testing in Males With Androgenetic Alopecia Active, not recruiting NCT02198261

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Genetic tests related to Alopecia, Androgenetic, 1:

id Genetic test Affiliating Genes
1 Alopecia, Androgenetic, 1 29

Anatomical Context for Alopecia, Androgenetic, 1

Publications for Alopecia, Androgenetic, 1

Variations for Alopecia, Androgenetic, 1

Expression for Alopecia, Androgenetic, 1

Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.

Pathways for Alopecia, Androgenetic, 1

GO Terms for Alopecia, Androgenetic, 1

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.55 CYP19A1 CYP21A2 SRD5A1 SRD5A2 STS
2 organelle membrane GO:0031090 9.13 CYP21A2 SRD5A1 SRD5A2
3 cell body fiber GO:0070852 8.62 SRD5A1 SRD5A2

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.75 AR CFLAR EDA2R
2 steroid metabolic process GO:0008202 9.67 CYP21A2 SRD5A1 SRD5A2 STS
3 male gonad development GO:0008584 9.62 AR SRD5A1 SRD5A2 TGFB2
4 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.61 AR CFLAR
5 cellular response to estradiol stimulus GO:0071392 9.61 CFLAR SRD5A1
6 cellular response to dexamethasone stimulus GO:0071549 9.6 CFLAR SRD5A1
7 sterol metabolic process GO:0016125 9.59 CYP19A1 CYP21A2
8 male genitalia development GO:0030539 9.58 SRD5A1 SRD5A2
9 response to testosterone GO:0033574 9.58 CFLAR SRD5A1 SRD5A2
10 uterus development GO:0060065 9.57 CYP19A1 TGFB2
11 hypothalamus development GO:0021854 9.56 SRD5A1 SRD5A2
12 androgen biosynthetic process GO:0006702 9.55 SRD5A1 SRD5A2
13 cellular response to testosterone stimulus GO:0071394 9.54 AR SRD5A1
14 progesterone metabolic process GO:0042448 9.52 SRD5A1 SRD5A2
15 prostate gland growth GO:0060736 9.51 AR CYP19A1
16 testosterone biosynthetic process GO:0061370 9.49 CYP19A1 SRD5A2
17 steroid catabolic process GO:0006706 9.48 SRD5A2 STS
18 response to follicle-stimulating hormone GO:0032354 9.46 SRD5A1 SRD5A2
19 positive regulation of integrin biosynthetic process GO:0045726 9.43 AR TGFB2
20 sex differentiation GO:0007548 9.43 AR SRD5A1 SRD5A2
21 androgen metabolic process GO:0008209 9.33 CYP19A1 SRD5A1 SRD5A2
22 steroid biosynthetic process GO:0006694 9.26 CYP19A1 CYP21A2 SRD5A1 SRD5A2
23 female genitalia development GO:0030540 8.8 CYP19A1 SRD5A1 SRD5A2

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 CYP19A1 CYP21A2 SRD5A1 SRD5A2
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.4 SRD5A1 SRD5A2
3 steroid hydroxylase activity GO:0008395 9.37 CYP19A1 CYP21A2
4 androgen binding GO:0005497 9.32 AR SHBG
5 amide binding GO:0033218 9.26 SRD5A1 SRD5A2
6 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.16 SRD5A1 SRD5A2
7 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A1 SRD5A2
8 steroid binding GO:0005496 8.8 AR CYP21A2 SHBG

Sources for Alopecia, Androgenetic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....